Nu-Med Plus, Inc. (NUMD) — SEC Filings
Nu-Med Plus, Inc. (NUMD) — 11 SEC filings. Latest: 10-Q (Nov 14, 2025). Includes 6 10-Q, 3 8-K, 2 10-K.
View Nu-Med Plus, Inc. on SEC EDGAR
Overview
Nu-Med Plus, Inc. (NUMD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: Nu-Med Plus, Inc. (NUMD) reported no revenue for the three and nine months ended September 30, 2025, consistent with the prior year. The company incurred a net loss of $11,966 for the three months ended September 30, 2025, an improvement from a net loss of $18,677 in the same period of 2024. For the
Sentiment Summary
Across 11 filings, the sentiment breakdown is: 3 bearish, 8 neutral. The dominant filing sentiment for Nu-Med Plus, Inc. is neutral.
Filing Type Overview
Nu-Med Plus, Inc. (NUMD) has filed 6 10-Q, 2 10-K, 3 8-K with the SEC between Mar 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (11)
| Date | Form | Description | Risk |
|---|---|---|---|
| Nov 14, 2025 | 10-Q | Nu-Med Plus Faces Going Concern Doubt Amid Zero Revenue, Mounting Debt | high |
| Aug 11, 2025 | 10-Q | Nu-Med Plus Remains Revenue-Less, Files 10-Q as Development Stage Firm | high |
| May 22, 2025 | 10-Q | Nu-Med Plus Narrows Q1 Loss by 90% Amidst Zero Revenue | high |
| Mar 31, 2025 | 10-K | Nu-Med Plus, Inc. Files 2024 Annual Report | low |
| Nov 14, 2024 | 10-Q | Nu-Med Plus, Inc. Files Q3 2024 10-Q Report | low |
| Oct 30, 2024 | 8-K | Nu-Med Plus Reports Acquisition, Control Change, Equity Sales | medium |
| Aug 21, 2024 | 10-Q | Nu-Med Plus Files Q2 2024 10-Q Report | low |
| May 15, 2024 | 10-Q | Nu-Med Plus, Inc. Files Quarterly Report on Form 10-Q for Period Ended March 31, 2024 | low |
| May 2, 2024 | 8-K | Nu-Med Plus Completes Asset Acquisition, Reports Control Changes | medium |
| Apr 29, 2024 | 8-K | Nu-Med Plus, Inc. Files 8-K for Material Agreement | medium |
| Mar 26, 2024 | 10-K | Nu-Med Plus, Inc. Files 2023 Annual Report on Form 10-K | low |
Risk Profile
Risk Assessment: Of NUMD's 11 recent filings, 3 were flagged as high-risk, 3 as medium-risk, and 5 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $(11,966) |
| EPS | $0.00 |
| Debt-to-Equity | N/A |
| Cash Position | $1,948 |
| Operating Margin | N/A |
| Total Assets | $5,048 |
| Total Debt | $263,708 |
Key Executives
- William Hayde
- Keith Merrell
Industry Context
Nu-Med Plus operates in the medical device field, focusing on designing, developing, and marketing technologies, particularly those utilizing nitric oxide. The company aims to address market niches in high-growth trend areas by improving existing medical procedures or devices or by creating solutions for unmet needs identified by medical professionals. The competitive landscape for medical devices is dynamic, requiring continuous innovation and significant capital investment for research, development, and regulatory approval.
Top Tags
SEC Filing (4) · 10-Q (3) · Medical Devices (2) · High Risk (2) · Quarterly Report (2) · 10-K (2) · quarterly-report (2) · medical-devices (2) · acquisition (2) · change-of-control (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue | $0 | for the three and nine months ended September 30, 2025, indicating no operational income |
| Net Loss | $(11,966) | for the three months ended September 30, 2025, an improvement from $(18,677) in 2024 |
| Cash on Hand | $1,948 | as of September 30, 2025, a decrease from $2,373 at December 31, 2024 |
| Total Liabilities | $263,708 | as of September 30, 2025, an increase from $224,469 at December 31, 2024 |
| Note Payable | $100,000 | to YourSpace America, Inc., maturing December 31, 2025 |
| Notes Payable – Related Parties | $100,000 | new debt issued on August 15, 2025, to entities owned by the CEO and CFO |
| Accumulated Deficit | $(9,936,896) | as of September 30, 2025, indicating significant historical losses |
| Planned Expenditures | $1,200,000 | estimated for the next twelve months, requiring additional funding |
| Common Shares Outstanding | 83,548,469 | as of November 14, 2025, with a par value of $0.001 |
| Form Type | 10-Q | The company filed a Quarterly Report under Section 13 or 15(d) of the Securities Exchange Act of 1934. |
| Conformed Period of Report | 20250630 | This date signifies the end of the financial period covered by the 10-Q filing. |
| Filed As Of Date | 20250811 | This is the official date the 10-Q was filed with the SEC. |
| Prior Net Loss | $10,000 | Net loss for Q1 2024, showing significant improvement in expense management. |
| Loss Reduction | 90% | Percentage decrease in net loss from Q1 2024 to Q1 2025. |
| Commission File Number | 000-54808 | Identifies the company's filings with the SEC. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Nu-Med Plus, Inc. (NUMD)?
Nu-Med Plus, Inc. has 11 recent SEC filings from Mar 2024 to Nov 2025, including 6 10-Q, 3 8-K, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of NUMD filings?
Across 11 filings, the sentiment breakdown is: 3 bearish, 8 neutral. The dominant sentiment is neutral.
Where can I find Nu-Med Plus, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Nu-Med Plus, Inc. (NUMD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Nu-Med Plus, Inc.?
Key financial highlights from Nu-Med Plus, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for NUMD?
The investment thesis for NUMD includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Nu-Med Plus, Inc.?
Key executives identified across Nu-Med Plus, Inc.'s filings include William Hayde, Keith Merrell.
What are the main risk factors for Nu-Med Plus, Inc. stock?
Of NUMD's 11 assessed filings, 3 were flagged high-risk, 3 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Nu-Med Plus, Inc.?
Forward guidance and predictions for Nu-Med Plus, Inc. are extracted from SEC filings as they are enriched.